Clinical trial · Observational
Real World Study of Four PD-1 Agents in China
Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China
NCT03966456CI-TRIAL-00038823unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdomen Tumors | — | UNRESOLVED | — |
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
| Thoracic Cancer | Malignant Thoracic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (4)
- label
- nivolumab
- description
- Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
- interventionNames
- Drug: Chemotherapy
- label
- pembrolizumab
- description
- Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
- interventionNames
- Drug: Chemotherapy
- label
- toripalimab
- description
- Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
- interventionNames
- Drug: Chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with lung cancer, liver cancer and other solid cancers * Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents * At least one measurable lesion * Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function Exclusion Criteria: * patients treated with PD-1 agents less than 2 terms
References
Publications (0)
Data not yet available
No reference posted for this study.